DXR Insider Filing Reveals Option Grant Pending SEC Plan Approval

Rhea-AI Filing Summary

Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan.

The options vest in three tranches—833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027—and expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Feuer Edward

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	2,500	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 2,500 shares (Direct)

Footnotes (1)

1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feuer Edward

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE, TN 37830

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$9.29	06/24/2025(1)		A		2,500		(2)	06/24/2030	COMMON STOCK	2,500	$0	2,500	D

Explanation of Responses:

1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").

2. The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834)

	/s/ Edward Feuer	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DXR report on 29 June 2025?

Director Edward Feuer received 2,500 stock options at a $9.29 exercise price, disclosed in the Form 4.

When do the newly awarded DXR options vest?

The options vest in three installments: 833 on 6/24/2025, 883 on 6/24/2026, and 834 on 6/24/2027.

Are there any conditions attached to Feuer’s DXR option grant?

Yes. The grant is contingent on SEC approval to amend the Daxor 2020 Incentive Compensation Plan.

What is the expiration date of the granted DXR options?

The options expire on 24 June 2030 if not exercised earlier.